NUVL Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -- compared to Nuvalent's net margin of -43.9%. Nuvalent's return on equity of -- beat Blueprint Medicines's return on equity of -50.13%.

Nuvalent has a consensus price target of $115.08, signalling upside risk potential of 60.14%. On the other hand Blueprint Medicines has an analysts' consensus of $125.47 which suggests that it could grow by 22.34%. Given that Nuvalent has higher upside potential than Blueprint Medicines, analysts believe Nuvalent is more attractive than Blueprint Medicines.

Nuvalent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.610, suggesting its less volatile than the S&P 500 by 39.048%.

Nuvalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Nuvalent quarterly revenues are --, which are smaller than Blueprint Medicines quarterly revenues of $128.2M. Nuvalent's net income of -$84.3M is lower than Blueprint Medicines's net income of -$56.3M. Notably, Nuvalent's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent is -- versus 14.81x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Citius Pharmaceuticals has a net margin of -- compared to Nuvalent's net margin of --. Nuvalent's return on equity of -- beat Citius Pharmaceuticals's return on equity of --.

Nuvalent has a consensus price target of $115.08, signalling upside risk potential of 60.14%. On the other hand Citius Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 995.51%. Given that Citius Pharmaceuticals has higher upside potential than Nuvalent, analysts believe Citius Pharmaceuticals is more attractive than Nuvalent.

Nuvalent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals has a beta of 1.302, suggesting its more volatile than the S&P 500 by 30.18%.

Nuvalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent pays -- of its earnings as a dividend. Citius Pharmaceuticals pays out -- of its earnings as a dividend.

Nuvalent quarterly revenues are --, which are smaller than Citius Pharmaceuticals quarterly revenues of --. Nuvalent's net income of -$84.3M is lower than Citius Pharmaceuticals's net income of -$10.8M. Notably, Nuvalent's price-to-earnings ratio is -- while Citius Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent is -- versus -- for Citius Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -- compared to Nuvalent's net margin of -6391.57%. Nuvalent's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

Nuvalent has a consensus price target of $115.08, signalling upside risk potential of 60.14%. On the other hand Janux Therapeutics has an analysts' consensus of $89.08 which suggests that it could grow by 97.69%. Given that Janux Therapeutics has higher upside potential than Nuvalent, analysts believe Janux Therapeutics is more attractive than Nuvalent.

Nuvalent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nuvalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Nuvalent quarterly revenues are --, which are smaller than Janux Therapeutics quarterly revenues of $439K. Nuvalent's net income of -$84.3M is lower than Janux Therapeutics's net income of -$28.1M. Notably, Nuvalent's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent is -- versus 176.84x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Nuvalent's net margin of --. Nuvalent's return on equity of -- beat Viking Therapeutics's return on equity of --.

Nuvalent has a consensus price target of $115.08, signalling upside risk potential of 60.14%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 182.92%. Given that Viking Therapeutics has higher upside potential than Nuvalent, analysts believe Viking Therapeutics is more attractive than Nuvalent.

Nuvalent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Nuvalent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Nuvalent quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Nuvalent's net income of -$84.3M is lower than Viking Therapeutics's net income of -$24.9M. Notably, Nuvalent's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.